Animal models of AIDS continue to surprise researchers with results that can be difficult to explain. However, most researchers still believe that animal models are essential to progress in understanding the disease. But which animal model is best? (pages 321–329)
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Abimiku, A.G. et al. HIV-1 recombinant pox virus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med. 1, 321–329 (1995).
Spouge, J.L. Statistical analysis of sparse infection data and its implication for retroviral treatment trials in primates. Proc. nail Acad. Sci. U.S.A. 89, 7581–7585 (1992).
Action on ‘Macaque Models for AIDS Research’. Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: Comparison of adjuvants, doses and challenge viruses. Vaccine 13, 295–300 (1995).
Berman, P. et al. Protection of chimpanzees from infection with HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 345, 622–625 (1990).
Fultz, P.N. et al. Vaccine protection of chimpanzees against challenge with HIV-1 infected peripheral blood mononuclear cells. Science 256, 1687–1690 (1992).
Emini, E. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain specific monoclonal antibody. Nature 355, 728–730 (1992).
Warren, J.T. et al. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in non-human primates: Progress in first and second order studies. J. med. Primatol. 22, 203–235 (1993).
Stott, E.J. et al. Anti cell antibody in macaques. Nature 353, 393 (1991).
Ahmed, S. et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res. hum. Retro. 10, 195–204 (1994).
Israel, Z.R. et al. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J. Virol. 68, 1843–1853 (1994).
Hu, S.L. et al Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255, 456–459 (1992).
Daniels, M.D. et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938–1941 (1992).
Shibata, R. et al. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 65, 3514–3520 (1991).
Kestler, H.W. et al. Importance of the nefgene for maintenance of high virus loads and development of AIDS. Cell 65, 651–662 (1991).
Rud, E. et al Molecular and biological characterization of simian immunodeficiency virus macaque strain 32H proviral clones containing nef size variants. J. gen. Virol. 75, 529–543 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stott, J., Almond, N. Assessing animal models of AIDS. Nat Med 1, 295–297 (1995). https://doi.org/10.1038/nm0495-295
Issue date:
DOI: https://doi.org/10.1038/nm0495-295
This article is cited by
-
HIV vaccines 1983–2003
Nature Medicine (2003)
-
Stand und gegenwärtige Strategien der HIV-Vakzineentwicklung
Der Internist (2003)
